Ensure Safe Use of CIMZIA
Serious and sometimes fatal side effects have been reported with CIMZIA, including
tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis),
and infections due to other opportunistic pathogens (such as Legionella or Listeria).
Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other
malignancies, some fatal, have been reported in children and adolescent patients
treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated
for use in pediatric patients.
To learn how to minimize these risks, read the Important Safety Information
provided on this page. Also, refer to the Medication Guide provided, and discuss
it with your doctor.